부설판

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Patients with known hypersensitivity to busulfan
• Patients who have shown resistance to the drug in the past
• Pregnancy (FDA Category D), unless potential benefits outweigh the risks
• Nursing dams

이상반응

• Myelosuppression (anemia, leukopenia, thrombocytopenia)
• Pancytopenia (can take months to years for recovery)
• Bronchopulmonary dysplasia with pulmonary fibrosis (uncommon, chronic use)
• Uric acid nephropathy
• Stomatitis

약물 상호작용

• Acetaminophen · Use within 72 hours prior to busulfan can reduce busulfan clearance by reducing glutathione concentrations in tissues and blood.
• Cyclophosphamide · Can potentially reduce clearance of busulfan, probably by competing for available glutathione.
• Itraconazole · Potential decreased busulfan clearance.
• Myelosuppressant agents · Concurrent use with other bone marrow depressant medications may result in additive myelosuppression.
• Phenytoin · Possible increased clearance of busulfan.
• Thioguanine · Used concomitantly with busulfan may result in hepatotoxicity.

모니터링

• CBC (Complete Blood Count)
• Serum uric acid
• Clinical efficacy

과용량

There is limited experience with busulfan overdoses. The LD50 in mice is 120 mg/kg. * **Chronic vs Acute**: Chronic overdosage is more likely to cause serious bone marrow suppression than is an acute overdose. * **Treatment**: Any overdose should be treated seriously with standard gut emptying protocols used when appropriate and supportive therapy initiated when required. * **Antidote**: There is no known specific antidote for busulfan intoxication.